A revolutionary approach to treating bowel cancer through pre-surgical immunotherapy has yielded promising results, significantly enhancing survival rates and reducing reliance on chemotherapy. A recent study demonstrated that none of the patients involved in the trial experienced a relapse, indicating a stark improvement over traditional treatment outcomes.
Groundbreaking Findings from UCL and UCLH
The innovative treatment is the result of a collaborative study led by University College London (UCL) alongside the University College London Hospitals NHS Foundation Trust (UCLH). The results were unveiled at the American Association for Cancer Research (AACR) meeting in San Diego, California, highlighting the potential of this new therapy.
This study builds upon previous findings that indicated a nine-week course of the immunotherapy drug pembrolizumab could lead to significant tumour shrinkage in patients diagnosed with stage two or three bowel cancer. Remarkably, 59% of participants showed no signs of disease following this treatment and their subsequent surgical procedures.
Now, more than 33 months after treatment, not a single patient has encountered a recurrence of cancer—an impressive statistic, especially compared to the historical norm where approximately 25% of patients experience a return of their cancer within three years following standard surgery and chemotherapy.
Details of the NEOPRISM-CRC Trial
The NEOPRISM-CRC trial included 32 patients with specific genetic profiles (MMR deficient/MSI-high), recruited from five hospitals across the UK. This genetic profile is present in about 10-15% of individuals with stage two or three bowel cancer, translating to roughly 2,000-3,000 new cases annually in the UK.
Such promising results from this select group have researchers optimistic about the wider applicability of this treatment method. Dr. Kai-Keen Shiu, chief investigator from the UCL Cancer Institute and consultant medical oncologist at UCLH, expressed his enthusiasm about the findings.
“Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging,” he stated. “It strengthens our confidence that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers.”
Personal Stories of Triumph
Among the patients involved in the trial is Christopher Burston, a 73-year-old man from Portland, Dorset. Diagnosed with bowel cancer following routine screening in February 2023, Burston received three doses of pembrolizumab over nine weeks before undergoing surgery.
“The outcome of the surgery was essentially that the cancer had melted away—these were the doctor’s words,” he reflected. Over three years later, he remains cancer-free, stating, “I feel very lucky that I’ve reached the stage where my main problem is age rather than cancer or any illness. I am able to play guitar, tend my garden, and walk the dog very much as before.”
Future Implications and Personalised Medicine
The study’s findings not only highlight the effectiveness of pembrolizumab but also signal a potential shift toward more personalised medicine in oncology. Researchers are now exploring how blood tests and immune profiling may assist in predicting which patients are most likely to respond to this treatment.
This could lead to a more tailored approach to therapy, allowing clinicians to determine which patients may benefit from less intensive treatment before and after surgery, while also identifying those who may require additional interventions due to a higher risk of disease progression.
Why it Matters
The implications of this research are profound, not only for the future of bowel cancer treatment but also for the broader field of oncology. As immunotherapy continues to demonstrate its potential in improving patient outcomes, it paves the way for innovative treatment pathways that could transform the lives of countless individuals facing similar diagnoses. This study represents a beacon of hope, offering new possibilities for recovery and quality of life for patients battling cancer.
